CLSA analysts downgraded Dr. Reddy's Laboratories shares, trading on both BSE (DRRD:IN) and NYSE (NYSE:RDY), from a Hold to an Underperform rating, adjusting the price target from INR1,140 to INR1,090 ...

The firm expects mid-single-digit price erosion in generic drugs and heightened competition for key medications, potentially ...

This steady growth in HDFC Bank's core earnings - both NII and net profit - came in despite a marginal rise in NPAs and NPA ...

This is the first time Indus Towers has received a ₹575 target, making it the highest among analysts covering the telecom ...

Newmont Corporation (NEM) stock saw a modest uptick, ending the day at $42.35 which represents a slight increase of $0.68 or 1.63% from the prior close of $41.67. The stock opened at $42.11 and ...

Finance companies' performance in the first half of 2025 is expected to be impacted by high credit costs due to unsecured credit. But it is seen normalising in the second half on underwriting ...

Vikash Kumar Jain, India Strategist and Head of Research at CLSA, predicts 2025 will be a year of consolidation for Indian markets. He noted that the consolidation trend, which began in October, could ...

The brokerage firm has also added Zomato to its high conviction outperform list, saying the recent correction is a buying ...

CLSA has initiated coverage on Hyundai Motor India with an 'Outperform' rating and a target price of Rs 2,155, citing strong ...

Shares of Zomato surged as much as 7.27% to reach INR 261.75 during the intraday trading session on the BSE today (January 16 ...

CLSA reaffirmed Bharti Airtel as Indias top telecom pick, citing robust growth potential and 5G expansion. Indus Towers, Tata ...